Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

This study has been completed.
Sponsor:
Collaborator:
Medarex
Information provided by:
University of Massachusetts, Worcester
ClinicalTrials.gov Identifier:
NCT00350298
First received: July 7, 2006
Last updated: October 26, 2010
Last verified: October 2010
  Purpose

Patients with Clostridium difficile associated disease who fulfill the eligibility criteria will be approached to participate. All study patients must receive standard of care treatment for Clostridium difficile associated disease. Enrolled patients will be randomized to receive a single intravenous solution of a human monoclonal antibody (huMab) to C. difficile toxin A (GS-CDA1) combined with a human monoclonal antibody to C. difficile toxin B (MDX-1388) or 0.9% sodium chloride as placebo in a 1:1 treatment allocation.Patients will be evaluated for safety and clinical outcomes through day 84 +/- 10 days. Occurrence of adverse events, use of concomitant medications, and stool output will be assessed at scheduled phone contacts and study visits. Some patients enrolled will have a subsequent visit on day 168 ± 14 days.


Condition Intervention Phase
Clostridium Infections
Biological: GS-CDA1
Biological: MDX-1388
Biological: normal saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease

Further study details as provided by University of Massachusetts, Worcester:

Primary Outcome Measures:
  • Determine if the addition of C. difficile toxin A and toxin B human monoclonal anti-toxin antibodies to standard of care treatment reduces the proportion of subjects with recurrent CDAD compared to standard of care and placebo. [ Time Frame: 3 Months Study Period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate safety and tolerability of human monoclonal anti-toxin antibodies in patients receiving standard of care treatment for CDAD compared to standard of care and placebo. [ Time Frame: 3 Months Study Period ] [ Designated as safety issue: Yes ]
  • Determine if the addition of human monoclonal antibodies to C. difficile toxin A and toxin B and standard of care treatment; reduces the time to resolution of diarrhea in patients with CDAD compared to standard of care and placebo. [ Time Frame: 3 Months Study Period ] [ Designated as safety issue: No ]
  • Determine if the addition of human monoclonal antibodies to C. difficile toxin A and toxin B and standard of care treatment; reduces the proportion of patients who experience standard of care treatment failure compared to standard of care and placebo. [ Time Frame: 3 Months Study Period ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: July 2006
Study Completion Date: October 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
GS-CDA1 and MDX-1388
Biological: GS-CDA1
one dose IV
Biological: MDX-1388
one dose IV
Placebo Comparator: 2
normal saline (0.9% sodium chloride)
Biological: normal saline
200ml IV once

Detailed Description:

This study is a phase II, randomized, double-blind, placebo-controlled study in patients diagnosed with Clostridium difficile associated disease. Patients with Clostridium difficile associated disease will be identified either from stool test results or by physician referral, and those who fulfill the eligibility criteria will be approached to participate. All study patients must receive standard of care treatment for Clostridium difficile associated disease. Enrolled patients will be randomized to receive a single intravenous solution of a human monoclonal antibody to C. difficile toxin A (GS-CDA1) combined with a human monoclonal antibody to C. difficile toxin B (MDX-1388) or 0.9% sodium chloride as placebo in a 1:1 treatment allocation. One hundred patients will be enrolled in the combination monoclonal antibody treated arm and 100 patients will be enrolled in the placebo arm. Patients will be evaluated through day 84 ± 10 days after receipt of study infusion for safety and clinical outcomes. Blood samples for safety analyses, anti-toxin A and anti-toxin B antibody measurements and human anti-human antibody (HAHA) titers will be collected at scheduled times. Study visits will occur on days 3 ± 1, 10 ± 2, 28 ± 3, 56 ± 7 and on day 84 ± 10 days. Occurrence of adverse events, use of concomitant medications, and record of stool output will be assessed at scheduled phone contacts and study visits. The first 20 patients enrolled will have a subsequent visit on day 168 ± 14 days for an additional blood collection for HAHA analysis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient > 18 years of age with diarrhea associated with a positive stool test for C. difficile toxin(s). Patients may be diagnosed with C. difficile by hospital/clinic/reference microbiology laboratory test or by a rapid diagnostic test performed by the study staff and positive test result must be within 14 days of enrollment.
  2. Patient must receive standard of care treatment for C. difficile associated disease. Standard of care treatment should include either metronidazole by mouth or intravenously or vancomycin by mouth.
  3. Patient or legal representative must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.

Exclusion Criteria:

  1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease.
  2. Score of 4 on modified Horn's index
  3. Severe C. difficile colitis with planned surgery in less than 24 hours.
  4. Positive pregnancy test within 24 hours of study infusion or an unwillingness to undergo pregnancy testing in females of child-bearing potential. Females capable of child-bearing must agree not to become pregnant from the time of study enrollment until at least 3 months after completion of study infusion. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel.
  5. Breastfeeding.
  6. Receipt of other investigational study agent within previous 30 days.
  7. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely the patient could complete the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00350298

  Show 29 Study Locations
Sponsors and Collaborators
University of Massachusetts, Worcester
Medarex
Investigators
Principal Investigator: Roger Baxter, MD Kaiser Permanente Vaccine Study Center
Principal Investigator: Herbert DuPont, MD St. Lukes Episcopal Hospital, Houston, TX
Principal Investigator: Joseph White, MD Scott and White Memorial Hospital, Temple, TX
Principal Investigator: David Chen, MD MultiCare Health System Research Services, Tacoma, WA
Principal Investigator: Jorge Reyno, MD Rapid City Regional Hospital, Rapid City, SD
Principal Investigator: Henry S. Sacks, MD, PhD Mount Sinai Hospital, New York, NY
Principal Investigator: Charles N. Bernstein, MD University of Manitoba, Health Sciences Centre, Winnepeg, Manitoba, Canada
Principal Investigator: Michael J. Tan, MD Summa Health Systems, Akron, Ohio
Principal Investigator: Michael C. Meadors, MD All-Trials Clinical Research, LLC, Winston-Salem, NC
Principal Investigator: Ian M. Baird, MD Remington-Davis Clinical Research
Principal Investigator: Andre Poirier, MD, MSc Centre Hospitalier Regional de Trois-Rivieres
Principal Investigator: Martha I. Buitrago, MD Idaho Falls Infectious Diseases, PLLC
Principal Investigator: Thomas Kovacs, MD UCLA CURE Digestive Diseases Research Center
Principal Investigator: Alfred Bacon, MD Christiana Care Health Systems
Principal Investigator: Kathleen Casey, MD Jersey Shore University Medical Center
Principal Investigator: C. Douglas Cochran, MD Saint Luke's Hospital of Kansas City
Principal Investigator: Donald Daly, MD Vancouver Island Health Research Centre
Principal Investigator: Anil Dhar, MBBS Windsor Regional Hospital
Principal Investigator: Gerald Evans, MD Kingston General Hospital
Principal Investigator: Richard Greenberg, MD University of Kentucky
Principal Investigator: Thomas Louie, MD University of Calgary Foothills Medical Center
Principal Investigator: Thomas Nowak, MD Central Indiana Gastroenterology Group
Principal Investigator: Jose Prieto, MD Dr. Kiran C. Patel Research Institute
Principal Investigator: Daniel Schroeder, MD Chest, Infectious Diseases and Critical Care Assoc., PC
Principal Investigator: Ann Silverman, MD Henry Ford Health System
Principal Investigator: John Pullman, MD Mercury Street Medical Group
Principal Investigator: Rodney J Mason, MD LAC/USC Medical Center
Principal Investigator: Doria Grimard, MD Centre de Sante et de Services Sociaux de Chicoutimi
Principal Investigator: Darrell Pardi, MD Mayo Clinic
  More Information

No publications provided by University of Massachusetts, Worcester

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Deborah Molrine, Massachusetts Biologic Laboratories
ClinicalTrials.gov Identifier: NCT00350298     History of Changes
Other Study ID Numbers: CA-GCDX-06-02
Study First Received: July 7, 2006
Last Updated: October 26, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Massachusetts, Worcester:
Monoclonal antibody,
Clostridium difficile Associated Diarrhea

Additional relevant MeSH terms:
Clostridium Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 25, 2014